Abstract:Based on the X-ray crystal structure of neuraminidase (NA), we chosed zanamivir, oseltamivir and peramivir as lead compounds, introduced phosphate ester groups to the corresponding amino group, and obtained ten new phosphamide derivatives, including C4 phosphorylated compounds of zanamivir and peramivir precursor, C5 phosphorylated compounds of oseltamivir. Their structures were confirmed by means of nuclear magnetic resonance spectmscopy (NMR) and high resolution mass spectrometry (HRMS). Molecular dynamics simulations were used to evaluate the interaction of new compounds with NA. Moreover, their abilities to inhibit neuraminidase and influenza viruses were tested. The preliminary results revealed that most new compounds possessed antiviral activities both in enzyme and cell levels. In particular, compound I-8 showed comparable inhibitory activities to oseltamivir with the half maximal inhibitory concentration (IC50) value of 0.397 nmol/L on NA-sensitive enzyme ( NAs) , while compound I-6 showed comparable inhibitory activities to oseltamivir with the IC50 value of 0.121 mu mol/L on influenza A H3N2, which might be the candidate compounds for further development. Our work might provide some insight into the rational design of anti-flu agents and the discovery of new effective drugs.

Discovery of Novel "Dual-Site" Binding Oseltamivir Derivatives As Potent Influenza Virus Neuraminidase Inhibitors.

Design, Synthesis and Biological Evaluation of "Multi-Site"-binding Influenza Virus Neuraminidase Inhibitors.

Discovery of C-1 Modified Oseltamivir Derivatives As Potent Influenza Neuraminidase Inhibitors.

Discovery of N-substituted oseltamivir derivatives as potent and selective inhibitors of H5N1 influenza neuraminidase.

Discovery of Acylguanidine Oseltamivir Carboxylate Derivatives As Potent Neuraminidase Inhibitors.

Optimization of N-Substituted Oseltamivir Derivatives As Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.

A Novel N-heterocycles Substituted Oseltamivir Derivatives As Potent Inhibitors of Influenza Virus Neuraminidase: Discovery, Synthesis and Biological Evaluation

Discovery of N-substituted oseltamivir derivatives as novel neuraminidase inhibitors with improved drug resistance profiles and favorable drug-like properties

Discovery of highly potent and selective influenza virus neuraminidase inhibitors targeting 150-cavity

Discovery of Novel 1,2,3-Triazole Oseltamivir Derivatives As Potent Influenza Neuraminidase Inhibitors Targeting the 430-Cavity

Iterative Optimization and Structure-Activity Relationship Studies of Oseltamivir Amino Derivatives as Potent and Selective Neuraminidase Inhibitors via Targeting 150-Cavity

Discovery of Novel Boron-Containing N-Substituted Oseltamivir Derivatives as Anti-Influenza A Virus Agents for Overcoming N1-H274Y Oseltamivir-Resistant

Structure-Based Optimization of N-Substituted Oseltamivir Derivatives As Potent Anti-Influenza A Virus Agents with Significantly Improved Potency Against Oseltamivir-Resistant N1-H274Y Variant

Discovery of Novel Boron-Containing <i>N</i>-Substituted Oseltamivir Derivatives as Anti-Influenza A Virus Agents for Overcoming N1-H274Y Oseltamivir-Resistant

Discovery of hydrazide-containing oseltamivir analogues as potent inhibitors of influenza A neuraminidase

Identification of C5-NH2 Modified Oseltamivir Derivatives as Novel Influenza Neuraminidase Inhibitors with Highly Improved Antiviral Activities and Favorable Druggability

Divalent Oseltamivir Analogues As Potent Influenza Neuraminidase Inhibitors.

Three New Powerful Oseltamivir Derivatives for Inhibiting the Neuraminidase of Influenza Virus.

Design, Synthesis, Biological Evaluation and In Silico Studies of Pyrazole-Based NH2-Acyl Oseltamivir Analogues as Potent Neuraminidase Inhibitors

The hydrophobic side chain of oseltamivir influences type A subtype selectivity of Neuraminidase inhibitors.

Design,Synthesis and Anti-influenza Activities of Novel Neuraminidase Inhibitors